Unique ID issued by UMIN | UMIN000009762 |
---|---|
Receipt number | R000011438 |
Scientific Title | Randomized phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and cyclophosphamide as conditioning regimen |
Date of disclosure of the study information | 2013/01/21 |
Last modified on | 2018/10/31 16:46:58 |
Randomized phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and cyclophosphamide as conditioning regimen
IVBU1001(BC): Randomized phase II study of once daily ivBu+Cy vs Cy+once daily ivBu
Randomized phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and cyclophosphamide as conditioning regimen
IVBU1001(BC): Randomized phase II study of once daily ivBu+Cy vs Cy+once daily ivBu
Japan |
acute myeloid leukemia(AML)
myelodysplastic syndrome(MDS)
chronic myelogenous leukemia(CML)
Hematology and clinical oncology |
Malignancy
NO
To investigate safety and efficacy of allogeneic hematopoietic stem cell transplantation using once daily intravenous busulfan(ivBu) and cyclophosphamide(Cy) as conditioning regimen for patients with AML, MDS and CML, with the comparison of order of application (ivBu+Cy vs Cy+ivBu) using randomized phase II trial design.
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
Probability of event-free survival at 1 year after transplantation
(1) Incidence of Bearman's grade 2 or higher adverse events which occur from the begining of conditioning regimen to 28 days after transplantation
(2) Cumulative incidence of engraftment at 100 days after transplantation
(3) Cumulative incidence of non-relapse mortality at 100 days after transplantation
(4) Cumulative incidence of SOS(sinusoidal obstrction syndrome) at 100 days after transplantation
(5) Cumulative incidence of grade II-IV acute GVHD at 1 year after transplantation
(6) Cumulative incidence of chronic GVHD at 1 year after transplantation
(7) Probability of overall survival and cumulative incidence of relapse at 1 year after transplantation
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is considered as a block.
YES
Central registration
2
Treatment
Medicine |
Conditioning regimen
Intravenous busulfan 3.2mg/kg/day x 4days + Cyclophosphamide 60mg/kg/day x 2days
Conditioning regimen
Cyclophosphamide 60mg/kg/day x 2days + Intravenous busulfan 3.2mg/kg/day x 4days
16 | years-old | <= |
55 | years-old | > |
Male and Female
(1) Patients between the age of 16 and 55 at informed consent
(2) Patients diagnosed as AML, MDS, CML who are eigible for allogeneic hematopoietic stem cell transplantation. No limitation of disease status at transplantation. Patients who need chemotherapy for disease control except imatinib, dasatinib and nilotinib for CML are excluded
(3) Patients who have the fixed schedule about the harvest of bone marrow or paripheral blood stem cells from related or unrelated donors who meet the following conditions:
1) HLA-A, B, DRB1 are genetically identical
2) HLA-A and B are genetically identical and 1 locus of HLA-DRB1 is genetically mismatched
(4) Patients whose performance status are 0 or 1 by ECOG criteria
(5) Patients who meet all of the following conditions:
1) SPO2>=94% by room air
2) sCr=<1.5mg/dL
3) T-bil=<1.5mg/dL
4) AST, ALT and ganma-GTP=<3 x upper limit of normal range
5) Absence of abnormal findings of ECG which require therapeutic interventions
6) Ejection fraction of left ventricle>=50% by UCG
(6) Patients who give written informed consent following sufficient explanation. Patients who are under 20 years old are required to give informed consent from both persons with parental authority and patients themselves
(1) Patients with uncontrolled diabetes mellitus in spite of regular use of insulin
(2) Patients with uncontrolled hypertension in spite of use of antihypertensive drugs
(3) Patients who have active infection
(4) Patients who are positive for TPHA, HBV surface antigen or anti-HCV antibody
(5) Patients who are positive for anti-HTLV-I or anti-HIV antibody
(6) Patients who are not evaluated to be able to survive more than 100 days after transplantation
(7) Patients who have coinciding active malignancies
(8) Patients who are pregnant or in the lactation period, and who are not able to, or not willing to prevent conception during the therapeutic period of this clinical trial
(9) Patients who have psychiatric disorder
(10) Patients who have prior hematopoietic stem cell transplantation
(11) Patients who are considered as inappropriate to register by attending physicians
68
1st name | |
Middle name | |
Last name | Takuya Yamashita |
National Cacer Center Hospital
Hematopoietic Stem Cell Transplantation Division
5-1-1, Tsukiji, Chuo, Tokyo
+81-3-3542-2511
tayamash@ncc.go.jp
1st name | |
Middle name | |
Last name | Takuya Yamashita |
National Cancer Center Hospital
Hematopoietic Stem Cell Transplantation Division
5-1-1, Tsukiji, Chuo, Tokyo
+81-3-3542-2511
tayamash@ncc.go.jp
Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital
The Ministry of Health, Labor and Welfare
Japanese Governmental office
Japan
NO
国立がん研究センター中央病院(東京都)
2013 | Year | 01 | Month | 21 | Day |
Unpublished
Completed
2012 | Year | 10 | Month | 03 | Day |
2013 | Year | 01 | Month | 21 | Day |
2015 | Year | 04 | Month | 30 | Day |
2018 | Year | 03 | Month | 31 | Day |
2018 | Year | 03 | Month | 31 | Day |
2019 | Year | 03 | Month | 31 | Day |
2013 | Year | 01 | Month | 12 | Day |
2018 | Year | 10 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011438
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |